WO2002004522A3 - Bifunctional molecules and vectors complexed therewith for targeted gene delivery - Google Patents

Bifunctional molecules and vectors complexed therewith for targeted gene delivery Download PDF

Info

Publication number
WO2002004522A3
WO2002004522A3 PCT/EP2001/007878 EP0107878W WO0204522A3 WO 2002004522 A3 WO2002004522 A3 WO 2002004522A3 EP 0107878 W EP0107878 W EP 0107878W WO 0204522 A3 WO0204522 A3 WO 0204522A3
Authority
WO
WIPO (PCT)
Prior art keywords
bifunctional molecules
gene delivery
targeted gene
methods
complexed therewith
Prior art date
Application number
PCT/EP2001/007878
Other languages
French (fr)
Other versions
WO2002004522A2 (en
Inventor
Glen R Nemerow
Erguang Li
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Scripps Research Inst
Glen R Nemerow
Erguang Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Scripps Research Inst, Glen R Nemerow, Erguang Li filed Critical Novartis Ag
Priority to EP01955340A priority Critical patent/EP1301541A2/en
Priority to IL15385301A priority patent/IL153853A0/en
Priority to AU2001277531A priority patent/AU2001277531A1/en
Priority to CA002414272A priority patent/CA2414272A1/en
Priority to JP2002509384A priority patent/JP2004502450A/en
Publication of WO2002004522A2 publication Critical patent/WO2002004522A2/en
Publication of WO2002004522A3 publication Critical patent/WO2002004522A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Methods and products for targeting delivery vectors, such as adenoviral gene delivery particles, to selected cell types are provided. The methods rely on targeting by a bifunctional molecule that specifically complexes with a protein on the vector particle surface and with targeted cell surface proteins. The targeted cell surface proteins are any that activate the phosphatidylinositol-3-OH kinases. The bifunctional molecules, compositions, kits, and methods of preparation and use of the vector/bifunctional molecules for gene therapy are provided.
PCT/EP2001/007878 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery WO2002004522A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01955340A EP1301541A2 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery
IL15385301A IL153853A0 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU2001277531A AU2001277531A1 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery
CA002414272A CA2414272A1 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery
JP2002509384A JP2004502450A (en) 2000-07-10 2001-07-09 Bifunctional molecules for targeting gene delivery and vectors conjugated therewith

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61301700A 2000-07-10 2000-07-10
US09/613,017 2000-07-10

Publications (2)

Publication Number Publication Date
WO2002004522A2 WO2002004522A2 (en) 2002-01-17
WO2002004522A3 true WO2002004522A3 (en) 2002-07-18

Family

ID=24455529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007878 WO2002004522A2 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Country Status (6)

Country Link
EP (1) EP1301541A2 (en)
JP (1) JP2004502450A (en)
AU (1) AU2001277531A1 (en)
CA (1) CA2414272A1 (en)
IL (1) IL153853A0 (en)
WO (1) WO2002004522A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
CN1542132A (en) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
MX2007006640A (en) 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
WO2006128679A2 (en) * 2005-05-31 2006-12-07 Martin Andreas Thurnher Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA2944647A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
WO2016118641A1 (en) 2015-01-20 2016-07-28 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
JP7058213B2 (en) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド Bonded molecule with modified J chain
CL2016000164A1 (en) * 2016-01-21 2016-07-29 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human adenovirus piii antigen (adv), produced and secreted by cellular hybridomas, useful for the detection and diagnosis of adv caused infection.
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
DE19849643A1 (en) * 1998-10-29 2000-05-04 Deutsches Krebsforsch Antibodies to the AAV capsid that change cell tropism and method for directed gene transfer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
DE19849643A1 (en) * 1998-10-29 2000-05-04 Deutsches Krebsforsch Antibodies to the AAV capsid that change cell tropism and method for directed gene transfer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E. LI ET AL.: "Production of functional antibodies generated in a nonlytic insect cell expression system.", PROTEIN EXPRESSION AND PURIFICATION, vol. 21, no. 1, February 2001 (2001-02-01), San Diego, CA, USA, pages 121 - 128, XP002198386 *
H. HAISMA ET AL.: "Targeting of adenoviral vectors through a bispecific single-chain antibody.", CANCER GENE THERAPY, vol. 7, no. 6, June 2000 (2000-06-01), Norwalk, CT, USA, pages 901 - 904, XP001064497 *
P. STEWART ET AL.: "Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization,", THE EMBO JOURNAL, vol. 16, no. 6, 17 March 1997 (1997-03-17), Oxford, GB, pages 1189 - 1198, XP002198385 *
S. WATKINS ET AL.: "Targeting adenovirus-mediated gene delivery with recombinant antibodies.", IMMUNOTECHNOLOGY, vol. 2, no. 4, 22 February 1996 (1996-02-22), Amsterdam, The Netherlands, pages 307, XP000672146 *
S. WATKINS ET AL.: "The "adenobody" approach to viral targeting: specific and enhanced adenoviral gene delivery.", GENE THERAPY, vol. 4, no. 10, October 1997 (1997-10-01), Basingstoke, GB, pages 1004 - 1012, XP002106261 *

Also Published As

Publication number Publication date
JP2004502450A (en) 2004-01-29
AU2001277531A1 (en) 2002-01-21
IL153853A0 (en) 2003-07-31
WO2002004522A2 (en) 2002-01-17
CA2414272A1 (en) 2002-01-17
EP1301541A2 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
WO2002004522A3 (en) Bifunctional molecules and vectors complexed therewith for targeted gene delivery
Kircheis et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery
Pai et al. The conformation of the poly (ethylene glycol) chain in mono-PEGylated lysozyme and mono-PEGylated human growth hormone
WO2004020595A8 (en) Novel human polypeptides encoded by polynucleotides
NZ595896A (en) Genetic products differentially expressed in tumors and the use thereof
Lim et al. Tumor regression following intravenous administration of lactoferrin-and lactoferricin-bearing dendriplexes
NZ504214A (en) Recombination cloning using nucleic acids having recombination sites
WO2011013130A3 (en) Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
Cho et al. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis
WO2005115477A3 (en) Non-natural ribonuclease conjugates as cytotoxic agents
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2002029072A3 (en) Targetting molecules for adenoviral vectors
WO2004074437A3 (en) Compositions and methods for cancer immunotherapy
WO2004046332A3 (en) Amplified genes involved in cancer
WO2003092579A3 (en) Compositions and methods for treating cancer with an oncolytic viral agent
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
WO1999036545A3 (en) Adenoviral vectors with modified capsid proteins
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO2000069454A8 (en) Suppression of endogenous igfbp-2 to inhibit cancer
NO20011817L (en) Ion exchange tumor targeting (IETT)
WO2006117694A3 (en) Genetically encoded photosensitizers and methods for using same
WO2003086276A3 (en) Compositions and methods for portal specific gene delivery and treatment of infection
FR2789588B1 (en) USE OF AN OMPA ENTEROBACTERIA PROTEIN ASSOCIATED WITH AN ANTIGEN IN A PHARMACEUTICAL COMPOSITION FOR GENERATING OR INCREASING ANTIVIRAL, PEST CONTROL OR ANTITUMOR CYTOTOXIC RESPONSE
WO2007076465A3 (en) Cln248 antibody compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001955340

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001277531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 153853

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 523555

Country of ref document: NZ

Ref document number: 2414272

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001955340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001955340

Country of ref document: EP